Pfizer (PFE) – Major News
-
Pfizer (PFE) Tops Q4 EPS by 28c, Tops on Revenue; Offers Guidance
-
Pfizer (PFE) Misses Q3 EPS by 9c; Reaffirms FY Outlook
-
Roche to acquire Telavant from Roivant and Pfizer for $7.25 billion
-
Pfizer (PFE) Tops Q2 EPS by 10c; Narrows FY Revenue Guidancce
-
Pfizer (PFE) Tops Q1 EPS by 25c; reaffirms guidance
-
Pfizer (PFE) Acquires Seagen (SGEN) for $43B or $229/sh
-
Pfizer (PFE) is in early talks to acquire Seagen (SGEN) - WSJ
-
Pfizer (PFE) Tops Q4 EPS by 7c; Guides FY 23 Below the Street
-
Pfizer (PFE) Tops Q3 EPS by 34, Beats on Revenue; Offers FY Guidance
-
Moderna (MRNA) Sues Pfizer (PFE) and BioNTech (BNTX) for Infringing Patents Central to Moderna's Innovative mRNA Technology Platform
-
Pfizer (PFE) in Global Blood Therapeutics (GBT) Takeover Talks
-
Pfizer (PFE) Tops Q2 EPS by 33c, Reaffirms FY22 Comirnaty and Paxlovid Sales Guidance
-
Pfizer (PFE) Acquires Biohaven Pharmaceuticals (BHVN) for $148.50/sh or $11.6B in Cash
-
Pfizer (PFE) Tops Q1 EPS by 15c, Guidance Misses Consensus
-
Zentalis Pharmaceuticals (ZNTL) Announces Pfizer (PFE) Acquired 953K Share Of the Company for $26.21/sh
-
Pfizer (PFE) Tops Q4 EPS by 20c, Revenue Misses, Guidance Falls Short of Views
-
Pfizer (PFE) to Acquire Arena Pharmaceuticals (ARNA) for $100 Per Share, $6.7 Billion Deal
-
Pfizer (PFE) Tops Q3 EPS by 29c, Raises FY Guidance
-
Pfizer (PFE) Tops Q2 EPS by 11c, Updates FY Guidance
-
Pfizer (PFE) Tops Q1 EPS by 15c, Raises FY Guidance
-
Pfizer (PFE) Misses Q4 EPS by 6c, Raises FY21 EPS Guidance
-
Pfizer (PFE), BioNTech (BNTX) COVID-19 Vaccine Receives FDA Emergency Use Authorization
-
Pfizer, BioNTech Covid-19 Vaccine 95% Effective, Request for EAU to Follow 'Within Days'
-
'The Most Significant Medical Breakthrough in 100 Years', 90% Effective Pfizer and BioNTech COVID-19 Vaccine Sends Stocks Surging
-
Pfizer (PFE), BioNTech (BNTX) COVID-19 Vaccine Shows Over 90% Efficacy in Phase 3 Study
-
Pfizer (PFE) Tops Q3 EPS by 1c, Updates FY Guidance
-
Pfizer (PFE) Tops Q2 EPS by 12c, Raises FY Guidance
-
Pfizer (PFE), BioNTech SE (BNTX) Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against COVID-19
-
Pfizer (PFE) Phase 3 PALLAS Trial of IBRANCE Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer Unlikely to Show Statistically Significant Improvement
-
Pfizer (PFE) Tops Q1 EPS by 7c, Reaffirms FY20 EPS Guidance
-
Pfizer (PFE) Misses Q4 EPS by 2c, Offers FY20 Guidance
-
Mylan (MYL), Pfizer (PFE) Said New Company to Be Named 'Viatris'
-
Pfizer (PFE) Tops Q3 EPS by 13c, Raises FY Guidance
-
UPDATE: Pfizer (PFE) Tops Q2 EPS by 5c, Revenues Miss; Lowers FY19 EPS/Revenue Guidance
-
Mylan (MYL) and Pfizer's (PFE) Upjohn to Combine
-
Mylan (MYL) in Talks to Merge with Pfizer's (PFE) Off-Patent Drug Business - Reports
-
Pfizer (PFE) to Acquire Array BioPharma (ARRY) in $11.4 Billion Deal, $48/Share
-
Pfizer (PFE) Tops Q1 EPS by 10c; Bumps EPS Outlook
-
Pfizer (PFE) Tops Q4 EPS by 1c, FY EPS Guidance Misses Consensus
-
Pfizer (PFE), GlaxoSmithKline (GSK) Enter Joint Venture Agreement to Create Premier Global Consumer Healthcare Company
-
Pfizer (PFE) Tops Q3 EPS by 3c
-
Pfizer (PFE) Elected Dr. Albert Bourla to Succeed Ian Read as CEO Effective January 1; Ian Read will Transition to Executive Chairman
-
Pfizer (PFE) Tops Q2 EPS by 7c, Updates Guidance
-
Pfizer (PFE) Tops Q1 EPS by 2c, Revenues Miss; Reaffirmed Guidance
-
Pfizer (PFE) Tops Q4 EPS by 6c, FY18 EPS Guidance Beats, Sees $15B Repatriation Tax Liability
-
Pfizer (PFE) Tops Q3 EPS by 2c, Lifts FY EPS Guidance
-
Pfizer (PFE) Says it's Reviewing Strategic Alternatives for Consumer Healthcare Business
-
Pfizer (PFE) Tops Q2 EPS by 1c, Updates FY EPS Guidance
-
Pfizer (PFE) Tops Q1 EPS by 2c, Offers FY Guidance
-
Pfizer (PFE) Misses Q4 EPS by 3c; Issues Lackluster Guidance
Back to PFE Stock Lookup